Roger E.G. Schutgens, MD, PhD, MSc

Internist-hematologist, Professor
Center for Benign Hematology, Thrombosis and Hemostasis, Van Creveldkliniek, University Medical Center Utrecht and University Utrecht, Utrecht, The Netherlands

Roger Schutgens is a Consultant Haematologist at the University Medical Centre Utrecht. His main responsibilities include care, research and education in the area of benign hematology and clotting diseases. Prof. Schutgens is the Head of the Van Creveldkliniek, a national expertise center for rare and inherited benign hematologic disorders, thrombosis and haemostasis. He completed his medical degree from Catholic University Leuven, Belgium and he completed his PhD from Utrecht University, The Netherlands. He is secretary of the Dutch Society for Thrombosis and Haemostasis. He has published over 185 peer reviewed articles. Prof. Schutgens areas of focus include patients predisposed to bleeding, congenital abnormalities of platelets and hypercoagulable conditions.

Presentation(s):

• OC 27.5 - Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B (OPTI-CLOT TARGET study) – Preliminary results

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• PB0078 - Lupus anticoagulant as predictor for thrombosis in critically ill COVID-19 patients: a retrospective cohort study

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 30.4 - Emicizumab real world experience using the entire-vial based dosing regimen in for patients with haemophilia A: AN UPDATE

  Monday, July 11, 2022
  11:30 AM – 11:45 AM

• OC 32.3 - Anti-β2-glycoprotein I antibodies cause activated protein C resistance by interfering with Factor V cleavage at Arginine 506

  Monday, July 11, 2022
  11:15 AM – 11:30 AM

• PB0719 - The novel bispecific antibody HMB-001 enhances the haemostatic response in models of Glanzmann Thrombasthenia by targeting FVIIa to activated platelets

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1162 - Safety of Non-Steroidal Anti-Inflammatory Drugs in hemophilia: a systematic review reporting on adverse bleeding and cardiovascular events

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1213 - Possible targets to reduce fatigue in chronic immune thrombocytopenia patients - an explorative study

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1214 - Effect of eltrombopag on platelet receptor expression and activation in patients with immune thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1216 - The association between vitamin D and disease activity in adult patients with chronic primary immune thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1247 - High bleeding rates in delta-storage pool disease

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 78.2 - Whole exome sequencing in patients with rare bleeding disorders: data from the RBiN study

  Wednesday, July 13, 2022
  10:30 AM – 10:45 AM

• OC 78.3 - HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

  Wednesday, July 13, 2022
  10:45 AM – 11:00 AM